Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Psyence Biomedical ( (PBM) ) has issued an announcement.
On August 28, 2025, Psyence Biomedical announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The event will allow the company to engage with global investors and present its business strategy and pipeline, emphasizing its unique approach in psychedelic medicine and its operational footprint in Africa. The company will also host a webinar for investors on September 16, 2025, to discuss its clinical development programs and strategic initiatives, further solidifying its position in the psychedelic medicine sector.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine therapies for mental health needs. It is a vertically integrated company and the first of its kind listed on Nasdaq, dedicated to addressing unmet mental health needs, particularly in palliative care.
Average Trading Volume: 1,650,515
Technical Sentiment Signal: Sell
Current Market Cap: $2.28M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.